Summary of evidence for 2019 surveillance of menopause (2015) NICE guideline NG23

References

1. Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, et al. (2017) Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause (New York, N.Y.) 24(3):238–46

2. Ensrud KE, Guthrie KA, Hohensee C, Caan B, Carpenter JS, Freeman EW, et al. (2015) Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes. Sleep 38(1):97–108

3. Yu C-G, Zhao S-H, Shi J-Y, Wang W-Z, Chen J-L (2016) A translational study of low-dose estrogen replacement therapy on Kupperman score and levels of hormones in patients with perimenopausal syndrome. Journal of international translational medicine 4(2):143–6

4. Caan B, LaCroix AZ, Joffe H, Guthrie KA, Larson JC, Carpenter JS, et al. (2015) Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause (New York, N.Y.) 22(6):607–15

5. Diem SJ, Guthrie KA, Mitchell CM, Reed S., Larson JC, Ensrud KE, et al. (2018) Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: A randomized clinical trial. Menopause 25(10):1086–93

6. Constantine GD, Revicki DA, Kagan R, Simon JA, Graham S, Bernick B, et al. (2019) Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms. Menopause (New York, N.Y.) 26(5):513–9

7. Kagan R, Constantine G, Kaunitz AM, Bernick B, Mirkin S (2018) Improvement in sleep outcomes with a 17beta-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women. Menopause (New York, N.Y.)

8. Paoletti AM, Cagnacci A, Di Carlo C, Orru MM, Neri M, D'Alterio MN, et al. (2015) Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 31(5):384–7

9. Gaudard A, Silva de SS, Puga M, Marjoribanks J, da SE, Torloni M (2016) Bioidentical hormones for women with vasomotor symptoms. Cochrane Database of Systematic Reviews (8)

10. Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, et al. (2016) Short?term and long?term effects of tibolone in postmenopausal women. Cochrane Database of Systematic Reviews (10)

11. Constantine GD, Simon JA, Pickar JH, Archer DF, Bernick B, Graham S, et al. (2018) Estradiol vaginal inserts (4 micro g and 10 micro g) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. Current Medical Research and Opinion 34(12):2131–6

12. Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH (2018) A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. Menopause 25(2):133–8

13. Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, et al. (2017) Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA internal medicine 177(10):1471–9

14. Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, et al. (2018) Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA internal medicine 178(5):681–90

15. Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, et al. (2017) The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause (New York, N.Y.) 24(4):409–16

16. Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH (2018) A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom. Journal of women's health (2002) 27(3):231–7

17. Rioux JE, Devlin MC, Gelfand MM, Steinberg WM, Hepburn DS (2018) 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 25(11):1208–13

18. Lethaby A, Ayeleke R, Roberts H (2016) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews (8)

19. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS (2018) Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial. JAMA Psychiatry 75(2):149–57

20. Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, et al. (2015) Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS medicine 12(6):e1001833–e1001833

21. Kingsberg SA, Kroll R, Goldstein I, Kushner H, Bernick B, Graham S, et al. (2017) Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR. Menopause (New York, N.Y.) 24(8):894–9

22. Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. (2016) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.) 23(3):243–56

23. Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 26(2):643–50

24. Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, et al. (2015) Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine 12(12):2401–12

25. Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, et al. (2019) Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause (New York, N.Y.)

26. Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA (2015) Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric : the journal of the International Menopause Society 18(2):226–32

27. Li Y, Liu H, Sun J, Tian Y, Li C (2016) Effect of melatonin on the peripheral T lymphocyte cell cycle and levels of reactive oxygen species in patients with premature ovarian failure. Experimental and Therapeutic Medicine 12(6):3589–94

28. Parandavar N, Hojat M, Abdali K, Keshtgar S, Emamghoreishi M, Yeganeh BS (2018) The effect of melatonin on the lipid levels in menopausal women: A double-blind, controlled, clinical trial. Journal of education and health promotion 7:144

29. Simon JA, Gaines T, LaGuardia KD, Group E-ROT for VMSS (2016) Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause (New York, N.Y.) 23(11):1214–21

30. Torky HA, Taha A, Marie H, El-Desouky E, Raslan O, Moussa AA, et al. (2018) Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric 21(2):174–8

31. Hardy C, Griffiths A, Norton S, Hunter MS (2018) Self-help cognitive behavior therapy for working women with problematic hot flushes and night sweats (MENOS@Work): a multicenter randomized controlled trial. Menopause (New York, N.Y.) 25(5):508–19

32. Atema V, van Leeuwen M, Kieffer JM, Oldenburg HSA, van Beurden M, Gerritsma MA, et al. (2019) Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 37(10):809–22

33. McCurry SM, Guthrie KA, Morin CM, Woods NF, Landis CA, Ensrud KE, et al. (2016) Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial. JAMA internal medicine 176(7):913–20

34. Huang AJ, Phillips S, Schembri M, Vittinghoff E, Grady D (2015) Device-guided slow-paced respiration for menopausal hot flushes. Obstetrics and gynecology 125:1130–8

35. Daley AJ, Thomas A, Roalfe AK, Stokes-Lampard H, Coleman S, Rees M, et al. (2015) The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG : an international journal of obstetrics and gynaecology 122(4):565–75

36. Abedi P, Nikkhah P, Najar S (2015) Effect of pedometer-based walking on depression, anxiety and insomnia among postmenopausal women. Climacteric : the journal of the International Menopause Society 18(6):841–5

37. Tadayon M, Abedi P, Farshadbakht F (2016) Impact of pedometer-based walking on menopausal women's sleep quality: a randomized controlled trial. Climacteric : the journal of the International Menopause Society 19(4):364–8

38. Gozuyesil E, Baser M (2016) The effect of foot reflexology applied to women aged between 40 and 60 on vasomotor complaints and quality of life. Complementary therapies in clinical practice 24:78–85

39. Almeida OP, Marsh K, Murray K, Hickey M, Sim M, Ford A, et al. (2016) Reducing depression during the menopausal transition with health coaching: Results from the healthy menopausal transition randomised controlled trial. Maturitas 92:41–8

40. Mirghafourvand M, Sehhatie Shafaie F, Jafari M (2015) Effects of self-directed learning on the early symptoms of menopause. Journal of babol university of medical sciences 17(3):68–75

41. Heudel P-E, Van Praagh-Doreau I, Duvert B, Cauvin I, Hardy-Bessard A-C, Jacquin J-P, et al. (2019) Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial. Supportive Care in Cancer 27(5):1879–89

42. Sathyapalan T, Aye M, Rigby AS, Thatcher NJ, Dargham SR, Kilpatrick ES, et al. (2018) Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause. Nutrition, metabolism, and cardiovascular diseases : NMCD 28(7):691–7

43. Gocan A, Imhof M, Schmidt M (2018) Soy germ extract alleviates menopausal hot flushes: Placebo-controlled double-blind trial. European Journal of Clinical Nutrition 72(7):961–70

44. Steels E, Steele M, Harold M, Adams L, Coulson S (2018) A double-blind, randomized, placebo-controlled trial evaluating safety and efficacy of an ayurvedic botanical formulation in reducing menopausal symptoms in otherwise healthy women. Journal of Herbal Medicine 11:30–5

45. Farshbaf-Khalili A, Kamalifard M, Namadian M (2018) Comparison of the effect of lavender and bitter orange on anxiety in postmenopausal women: A triple-blind, randomized, controlled clinical trial. Complementary therapies in clinical practice 31:132–8

46. Kamalifard M, Farshbaf-Khalili A, Namadian M, Ranjbar Y, Herizchi S (2018) Comparison of the effect of lavender and bitter orange on sleep quality in postmenopausal women: A triple-blind, randomized, controlled clinical trial. Women & health 58(8):851–65

47. Dastenaei BM, Safdari F, Jafarzadeh L, Dehkordi ZR, Taghizadeh M, Nikzad M (2017) The effect of evening primrose on hot flashes in menopausal women. Iranian journal of obstetrics, gynecology and infertility 20(10):62–8

48. Steels E, Steele ML, Harold M, Coulson S (2017) Efficacy of a Proprietary Trigonella foenum-graecum L. De-Husked Seed Extract in Reducing Menopausal Symptoms in Otherwise Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Study. Phytotherapy research : PTR 31(9):1316–22

49. Aghamiri V, Mirghafourvand M, Mohammad-Alizadeh-Charandabi S, Nazemiyeh H (2016) The effect of Hop (Humulus lupulus L.) on early menopausal symptoms and hot flashes: A randomized placebo-controlled trial. Complementary therapies in clinical practice 23:130–5

50. Kazemzadeh R, Nikjou R, Rostamnegad M, Norouzi H (2016) Effect of lavender aromatherapy on menopause hot flushing: A crossover randomized clinical trial. Journal of the Chinese Medical Association : JCMA 79(9):489–92

51. Nikjou R, Kazemzadeh R, Asadzadeh F, Fathi R, Mostafazadeh F (2018) The Effect of Lavender Aromatherapy on the Symptoms of Menopause. Journal of the National Medical Association 110(3):265–9

52. Zhu X, Liew Y, Liu Z (2016) Chinese herbal medicine for menopausal symptoms. Cochrane Database of Systematic Reviews (3)

53. Jiang D, Zhou J-H, Zhou J, Gu Y-E, Yang D-X, Weng Q, et al. (2015) Zhi-bai-di-huang-wan, a classic chinese medicinal formula in relieving menopausal symptoms: A multi-centre and controlled trial from UK and China. African Journal of Traditional, Complementary and Alternative Medicines 12(s1):45–51

54. Li O, Wang F (2018) Acupuncture at back-shu points of five zang, Geshu (BL 17) and Shenmen (HT 7) for the treatment of menopausal insomnia. Zhongguo zhen jiu [Chinese acupuncture & moxibustion] 38(5):4672–93

55. Avis NE, Coeytaux RR, Isom S, Prevette K, Morgan T (2016) Acupuncture in Menopause (AIM) study: a pragmatic, randomized controlled trial. Menopause (New York, N.Y.) 23(6):626–37

56. Liu Z, Ai Y, Wang W, Zhou K, He L, Dong G, et al. (2018) Acupuncture for symptoms in menopause transition: a randomized controlled trial. American Journal of Obstetrics and Gynecology 219(4):373

57. Ee C, Xue C, Chondros P, Myers SP, French SD, Teede H, et al. (2016) Acupuncture for Menopausal Hot Flashes: A Randomized Trial. Annals of internal medicine 164(3):146–54

58. Lesi G, Razzini G, Musti MA, Stivanello E, Petrucci C, Benedetti B, et al. (2016) Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34(15):1795–802

59. Peng YY, Jing HT, Luan L, Tu YY (2018) Treatment of Menopausal Syndrome by Combined Electroacupuncture, Acupoint-injection and Fire-needle Therapies. Zhen CI yan jiu = acupuncture research 43(4):260–2

60. Crandall CJ, Hovey KM, Andrews CA, Chlebowski R., Stefanick ML, Lane DS, et al. (2018) Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 25(1):11–20

61. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, et al. (2016) Vaginal estradiol use and the risk for cardiovascular mortality. Human reproduction (Oxford, England) 31(4):804–9

62. Carrasquilla GD, Frumento P, Berglund A, Borgfeldt C, Bottai M, Chiavenna C, et al. (2017) Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies. PLoS medicine 14(11):e1002445

63. Chang W-C, Wang J-H, Ding D-C (2019) Hormone therapy in postmenopausal women associated with risk of stroke and venous thromboembolism: a population-based cohort study in Taiwan. Menopause (New York, N.Y.) 26(2):197–202

64. Chen Y-H, Hsieh T-F, Lee C-C, Wu M-J, Fu Y-C (2015) Estrogen therapy and ischemic stroke in women with diabetes aged over 55 Years: A nation-wide prospective population-based study in Taiwan. PLoS ONE 10(12):144910

65. Lokkegaard E, Nielsen LH, Keiding N (2017) Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke 48(8):2266–9

66. Qureshi AI, Malik AA, Saeed O, Defillo A, Sherr GT, Suri MFK (2016) Hormone replacement therapy and the risk of subarachnoid hemorrhage in postmenopausal women. Journal of neurosurgery 124(1):45–50

67. Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, et al. (2015) Increased Cardiovascular Mortality Risk in Women Discontinuing Postmenopausal Hormone Therapy. The Journal of clinical endocrinology and metabolism 100(12):4588–94

68. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (2017) Long?term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews (1)

69. Gartlehner G, Patel S V, Feltner C, Weber RP, Long R, Mullican K, et al. (2017) Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 318(22):2234–49

70. Lee C-H, Cheng C-L, Kao Yang Y-H, Lin L-J (2015) Hormone therapy and risk of venous thromboembolism among postmenopausal women in Taiwan - a 10-year nationwide population-based study. Circulation journal : official journal of the Japanese Circulation Society 79(5):1107–14

71. Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D (2018) Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause (New York, N.Y.) 25(11):1286–90

72. Dinger J, Bardenheuer K, Heinemann K (2016) Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric : the journal of the International Menopause Society 19(4):349–56

73. Swica Y, Warren MP, Manson JE, Aragaki AK, Bassuk SS, Shimbo D, et al. (2018) Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials. Menopause (New York, N.Y.) 25(7):753–61

74. Ki EY, Hur SY, Park JS, Do Han K, Park YG (2016) Differences in the lipid profile and hormone replacement therapy use in Korean postmenopausal women: the Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012. Archives of gynecology and obstetrics 294(1):165–73

75. Chen L, Mishra GD, Dobson AJ, Wilson LF, Jones MA (2017) Protective effect of hormone therapy among women with hysterectomy/oophorectomy. Human reproduction (Oxford, England) 32(4):885–92

76. Holm M, Olsen A, Au Yeung SL, Overvad K, Lidegaard O, Kroman N, et al. (2019) Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG : an international journal of obstetrics and gynaecology 126(1):55–63

77. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. (2017) Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA 318(10):927–38

78. Brusselaers N, Tamimi RM, Konings P, Rosner B, Adami H-O, Lagergren J (2018) Different menopausal hormone regimens and risk of breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 29(8):1771–6

79. Ettinger B, Quesenberry C, Schroeder DA, Friedman G (2018) Long-term postmenopausal estrogen therapy may be associated with increased risk of breast cancer: a cohort study. Menopause (New York, N.Y.) 25(11):1191–4

80. Holm M, Olsen A, Kyrø C, Overvad K, Kroman N, Tjønneland A (2018) The Influence of Menopausal Hormone Therapy and Potential Lifestyle Interactions in Female Cancer Development-a Population-Based Prospective Study. Hormones & cancer 9(4):254–64

81. Liu J-Y, Chen T-J, Hwang S-J (2016) The Risk of Breast Cancer in Women Using Menopausal Hormone Replacement Therapy in Taiwan. International journal of environmental research and public health 13(5)

82. Obi N, Heinz J, Seibold P, Vrieling A, Rudolph A, Chang-Claude J, et al. (2016) Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort. International journal of cancer 138(9):2098–108

83. Siegelmann-Danieli N, Katzir I, Landes JV, Segal Y, Bachar R, Rabinovich HR, et al. (2018) Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Breast cancer research and treatment 167(1):257–62

84. Simin J, Tamimi R, Lagergren J, Adami H-O, Brusselaers N (2017) Menopausal hormone therapy and cancer risk: An overestimated risk?. European journal of cancer (Oxford, England : 1990) 84:60–8

85. Suhrke P, Zahl P-H (2015) Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study. Cancer medicine 4(8):1303–8

86. Jones ME, Schoemaker MJ, Wright L, McFadden E, Griffin J, Thomas D, et al. (2016) Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?. British journal of cancer 115(5):607–15

87. Chlebowski RT, Anderson GL, Aragaki AK, Prentice R (2016) Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index. Journal of the National Cancer Institute 108(2)

88. Morch LS, Lidegaard O, Keiding N, Lokkegaard E, Kjaer SK (2016) The influence of hormone therapies on colon and rectal cancer. European journal of epidemiology 31(5):481–9

89. Sadr-Azodi O, Konings P, Brusselaers N (2017) Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study. United European gastroenterology journal 5(8):1123–8

90. Zamora-Ros R, Rinaldi S, Biessy C, Tjonneland A, Halkjaer J, Fournier A, et al. (2015) Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: the EPIC study. International journal of cancer 136(5):1218–27

91. Blanks RG, Benson VS, Alison R, Brown A, Reeves GK, Beral V, et al. (2015) Nationwide bowel cancer screening programme in England: cohort study of lifestyle factors affecting participation and outcomes in women. British journal of cancer 112(9):1562–7

92. Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, et al. (2017) Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? International journal of cancer 141(9):1763–70

93. Botteri E, Stoer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, et al. (2017) Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway. BMJ open 7(11):e017639

94. Brusselaers N, Maret-Ouda J, Konings P, El-Serag HB, Lagergren J (2017) Menopausal hormone therapy and the risk of esophageal and gastric cancer. International journal of cancer 140(7):1693–9

95. Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, Savoye I, Boutron-Ruault MC, Fournier A, et al. (2019) Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study. International journal of cancer

96. Cancer CGOESOO, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, et al. (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet (London, England) 385(9980):1835–42

97. Kilander C, Lagergren J, Konings P, Sadr-Azodi O, Brusselaers N (2019) Menopausal hormone therapy and biliary tract cancer: a population-based matched cohort study in Sweden. Acta oncologica (Stockholm, Sweden) 58(3):290–5

98. Løkkegaard ECL, Mørch LS (2018) Tibolone and risk of gynecological hormone sensitive cancer. International journal of cancer 142(12):2435–40

99. Chlebowski RT, Wakelee H, Pettinger M, Rohan T, Liu J, Simon M, et al. (2016) Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. Clinical lung cancer 17(1):10–7.e1

100. Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, et al. (2015) Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33(35):4138–44

101. Kato I, Chlebowski RT, Hou L, Wactawski-Wende J, Ray RM, Abrams J, et al. (2016) Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial. International journal of cancer 138(3):604–11

102. Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, et al. (2016) Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. Journal of the National Cancer Institute 108(3)

103. Edey K, Rundle S, Hickey M (2018) Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database of Systematic Reviews (5)

104. Kuh D, Muthuri S, Cooper R, Moore A, Mackinnon K, Cooper C, et al. (2016) Menopause, Reproductive Life, Hormone Replacement Therapy, and Bone Phenotype at Age 60-64 Years: A British Birth Cohort. The Journal of clinical endocrinology and metabolism 101(10):3827–37

105. Saarelainen J, Hassi S, Honkanen R, Koivumaa-Honkanen H, Sirola J, Kroger H, et al. (2016) Bone loss and wrist fractures after withdrawal of hormone therapy: The 15-year follow-up of the OSTPRE cohort. Maturitas 85:49–55

106. Watts NB, Cauley JA, Jackson RD, LaCroix AZ, Lewis CE, Manson JE, et al. (2017) No Increase in Fractures After Stopping Hormone Therapy: Results From the Women's Health Initiative. The Journal of clinical endocrinology and metabolism 102(1):302–8

107. Imtiaz B, Tuppurainen M, Rikkonen T, Kivipelto M, Soininen H, Kroger H, et al. (2017) Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. Neurology 88(11):1062–8

108. Espeland MA, Rapp SR, Manson JE, Goveas JS, Shumaker SA, Hayden KM, et al. (2017) Long-term Effects on Cognitive Trajectories of Postmenopausal Hormone Therapy in Two Age Groups. The journals of gerontology. Series A, Biological sciences and medical sciences 72(6):838–45

109. Espeland MA, Brinton RD, Manson JE, Yaffe K, Hugenschmidt C, Vaughan L, et al. (2015) Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes. Neurology 85(13):1131–8

110. Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, et al. (2016) Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. Neurology 87(7):699–708

111. Paganini-Hill A, Corrada MM, Kawas CH (2018) Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause (New York, N.Y.) 25(11):1256–61

112. Bengtsson C, Malspeis S, Orellana C, Sparks JA, Costenbader KH, Karlson EW (2017) Association Between Menopausal Factors and the Risk of Seronegative and Seropositive Rheumatoid Arthritis: Results From the Nurses' Health Studies. Arthritis care & research 69(11):1676–84

113. Chlebowski RT, Cirillo DJ, Eaton CB, Stefanick ML, Pettinger M, Carbone LD, et al. (2018) Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause (New York, N.Y.) 25(11):1313–20

114. Curhan SG, Eliassen AH, Eavey RD, Wang M, Lin BM, Curhan GC (2017) Menopause and postmenopausal hormone therapy and risk of hearing loss. Menopause (New York, N.Y.) 24(9):1049–56

115. Sommer EM, Balkwill A, Reeves G, Green J, Beral DV, Coffey K, et al. (2015) Effects of obesity and hormone therapy on surgically-confirmed fibroids in postmenopausal women. European journal of epidemiology 30(6):493–9

116. Staller K, Townsend MK, Khalili H, Mehta R, Grodstein F, Whitehead WE, et al. (2017) Menopausal Hormone Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause. Gastroenterology 152(8):1915–1921e1

117. Kattah AG, Suarez MLG, Milic N, Kantarci K, Zeydan B, Mosley T, et al. (2018) Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis. Menopause (New York, N.Y.) 25(6):625–34

118. Al-Rousan T, Sparks JA, Pettinger M, Chlebowski R, Manson JE, Kauntiz AM, et al. (2018) Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative. PloS one 13(12):e0207509

119. Triebner K, Accordini S, Calciano L, Johannessen A, Benediktsdottir B, Bifulco E, et al. (2019) Exogenous female sex steroids may reduce lung ageing after menopause: A 20-year follow-up study of a general population sample (ECRHS). Maturitas 120:29–34

120. Chen P-J, Chung C-H, Chien W-C, Chen H-C (2019) Hormone therapy is not associated with the risk of sudden sensorineural hearing loss in postmenopausal women: a 10-year nationwide population-based study. Menopause (New York, N.Y.) 26(8):892–8

121. Vajaranant TS, Maki PM, Pasquale LR, Lee A, Kim H, Haan MN (2016) Effects of Hormone Therapy on Intraocular Pressure: The Women's Health Initiative-Sight Exam Study. American journal of ophthalmology 165:115–24

122. Crandall CJ, Hovey KM, Andrews C, Cauley JA, Stefanick M, Shufelt C, et al. (2017) Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study. Menopause (New York, N.Y.) 24(10):1145–53

© NICE 2019. All rights reserved. Subject to Notice of rights.